Reviews/Heart Failure Management/Angiotensin receptor-neprilysin inhibitor reduces mortality versus ACE inhibitor or angiotensin receptor blocker in heart failure with reduced ejection fraction
Pharm · HFM-PHARM-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The claim says sacubitril/valsartan lowers both death from any cause and heart failure hospital admissions compared with older ACE inhibitor or ARB blood-pressure drugs in people whose hearts pump weakly. One large, carefully blinded trial directly tested it against an ACE inhibitor and found fewer deaths and fewer hospitalisations [9]. A separate nationwide records study of routine patients found the same survival advantage against a mix of the older drugs [10], but did not see fewer hospitalisations there. So the survival half of the claim is backed twice over, while the hospitalisation half and the comparison specifically against ARBs each rest on only one source. The panel landed just short of its top tier because those two limbs are not yet independently confirmed.
The pivotal double-blind trial [9] randomised 8442 HFrEF patients to sacubitril/valsartan or the ACE inhibitor enalapril and reported a hazard ratio for death from any cause of 0.84 and a 21% reduction in hospitalisation for heart failure, both highly significant. The nationwide Danish cohort [10] matched 2,446 ARNI initiators to 4,892 ACE-I or ARB users and reproduced the survival signal with a hazard ratio of 0.85 for all-cause mortality and 0.81 for cardiovascular death. Both studies sit directly on HFrEF, the drug, and the comparator class. Only these two papers cleared the Methodologist's relevance filter; the remaining eight were wrong drug, wrong population, or not an outcome comparison. The contested point: The division is over the hospitalisation limb and the ARB comparator: the trial [9] shows a hospitalisation benefit against an ACE inhibitor, but the registry [10] explicitly found ARNI was not associated with the other secondary outcomes, i.e. no hospitalisation benefit. The ARB arm of the comparator appears only inside [10]'s pooled, observational ACE-I/ARB group, with no dedicated ARB-controlled trial.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal RCT [9] compares sacubitril/valsartan only against enalapril, an ACE inhibitor; the claim's 'or ARB' limb has no head-to-head RCT and rests solely on the pooled, confounding-prone observational arm of [10].
The HF-hospitalisation half of the compound outcome is confirmed in only one trial; registry cohort [10] explicitly found no benefit for 'other secondary outcomes', so the real-world evidence is discordant on hospitalisation.
Where it remains uncertain. The registry [10] did not find a hospitalisation benefit, so half the compound outcome is confirmed only in [9], and the ARB comparator exists only in [10]'s pooled observational arm.
Aleatory
The pivotal trial [9] was stopped early for overwhelming benefit after a median 27 months, which can inflate observed effect estimates by chance.
Epistemic
No trial in the corpus tests sacubitril/valsartan against an ARB; the comparator is known only through the pooled observational arm of [10].
Inferential
[10] is a prevalent new-user propensity-matched cohort; residual confounding and selection bias can survive matching despite a significant hazard ratio.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes the all-cause mortality reduction vs an ACE inhibitor in HFrEF.
“As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001)”
Panel auditInternal validity: high · scope of inference: Patients with class II-IV heart failure and ejection fraction ≤40% comparing sacubitril/valsartan with enalapril.Key limitations: comparator is enalapril only, not the full ACEi/ARB class · early stopping may inflate effect
Independent real-world confirmation of the mortality benefit, adding the ARB comparator.
“ARNI was also associated with a lower risk of cardiovascular death (HR, 0.81; 95% CI, 0.65 to 0.99), but not with other secondary outcomes.”
Panel auditInternal validity: medium · scope of inference: Routine-practice effectiveness of ARNI versus ACE-I/ARB in Danish patients with LVEF ≤40%, 2018-2023.Key limitations: observational, residual confounding · hospitalisation not reduced · mortality benefit only for one half of the claim
2 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, robust mortality evidence across an RCT and a real-world cohort supports the claim, but single-trial dependence for hospitalisation and the indirect ARB comparator hold it just below the Established tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No ARB head-to-head trial. The claim names ARB therapy as a comparator, but every randomised comparison in the corpus uses an ACE inhibitor [9]; the ARB arm survives only inside a pooled observational group [10]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial of sacubitril/valsartan versus an ARB in HFrEF with mortality and HF hospitalisation endpoints.
Open question: Does sacubitril/valsartan reduce death and HF hospitalisation compared with ARB therapy specifically? Why it is still open: The only randomised comparator in the corpus is the ACE inhibitor enalapril [9]; the ARB comparator exists only in [10]'s pooled observational arm.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19